Literature DB >> 3922039

Detection of anti-extractable nuclear antigens in connective tissue diseases: comparison between passive hemagglutination, counterimmunoelectrophoresis and double immunodiffusion.

A Siracusano, M Agelli, S Ioppolo, F Quintieri, S Bombardieri.   

Abstract

Antibodies to the three major components of the complex called soluble extractable nuclear antigen (ENA) were detected by passive hemagglutination (HA), counterimmunoelectrophoresis (CIE) and double immunodiffusion (DI) in 256 patients with connective tissue diseases. Anti-ENA antibodies were demonstrated by all the three employed methods in only 44.9% of the cases. These methods were not able to detect all antibodies to these antigens or any single specificity; CIE was however the most sensitive method for anti-RNP and HA for anti-Sm antibodies, while DI was the most suitable technique for serum samples with multiple anti-ENA specificities. Only in less than 50% of the cases the specificity detected by HA was comparable with that given by CIE or DI. Hence, for detecting anti-ENA antibodies a combination of these methods should be maintained, at least until more precise and reliable methods will become available.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3922039     DOI: 10.1007/bf03029159

Source DB:  PubMed          Journal:  Ric Clin Lab        ISSN: 0390-5748


  3 in total

1.  Antibodies to extractable nuclear antigens. Has technological drift affected clinical interpretation?

Authors:  R J Lock; D J Unsworth
Journal:  J Clin Pathol       Date:  2001-03       Impact factor: 3.411

2.  Antinuclear antibodies and their detection methods in diagnosis of connective tissue diseases: a journey revisited.

Authors:  Yashwant Kumar; Alka Bhatia; Ranjana Walker Minz
Journal:  Diagn Pathol       Date:  2009-01-02       Impact factor: 2.644

3.  Detection of Anti-Extractable Nuclear Antigens in Patients with Systemic Rheumatic Disease via Fluorescence Enzyme Immunoassay and Its Clinical Utility.

Authors:  Joowon Oh; Younhee Park; Kyung A Lee; Hyon Suk Kim
Journal:  Yonsei Med J       Date:  2020-01       Impact factor: 2.759

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.